Abstract
Tislelizumab (TIS) demonstrated statistically and clinically significant improvement in overall survival (OS) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic esophageal squamous cell carcinoma (ESCC) in the global phase 3 study RATIONALE 302 (NCT03430843). Here, we report results for the Japanese subgroup.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
